Biopharma AI
By
Adaptive Biotechnologies and Pfizer Announce Strategic Research Collaboration Valued Up to $890 Million to Advance Breakthrough Therapies for Rheumatoid Arthritis and Immune-Mediated Diseases
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis. A data licensing agreement to…
Is Merck and Nvidia’s KERMT Model the Breakthrough That Finally Makes AI-Native Drug Discovery Faster, Greener, and More Predictive?
Key Highlights / Executive Takeaways: • Merck and Nvidia introduce KERMT, a next-generation small-molecule AI model trained on…
Will LabGenius Therapeutics and Sanofi’s Second AI-Powered Alliance Accelerate the Next Wave of Antibody and NANOBODY® Innovation in Inflammatory Diseases?
Key Highlights / Executive Takeaways: • Expanded collaboration deepens trust between LabGenius Therapeutics and Sanofi, reinforcing AI/ML as…
Can Phare Bio and Basilea’s AI-Driven Alliance Redefine Antibiotic Discovery and Change the Fight Against Drug-Resistant Infections Worldwide?
Executive Takeaways: • First-of-its-kind partnership aligns AI-driven antibiotic design directly with patient-centric target product profiles, setting a new…
Can Gilead’s $260 Million AI Investment in 2025 — Backed by Strategic AI Initiatives — Accelerate Discovery, R&D, and Commercial Impact in 2026?
Global – December 31, 2025 — Gilead Sciences, Inc. expanded its commitment to artificial intelligence (AI) throughout 2025…
Can Sanofi’s $380 Million AI Investment in 2025 — Bolstered by Strategic Partnerships — Drive Breakthroughs in Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — Sanofi S.A. made significant investments in artificial intelligence (AI) across discovery, clinical…
